Alkermes News

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced that BYDUREON is now available by prescription in U.S. pharmacies.

16, 2012, at 3:00 p.m. EST from the Waldorf=Astoria Hotel in New York City. The presentation may be accessed under the Investor tab on www.alkermes.com and will be archived for 14 days.

PriceWaterhouseCoopers, along with the California Healthcare Institute and Bay Bio has released a study saying that the California biomedical industry "is on a precipice," and employment has stalled.

"In 2011, Elan made substantial progress across all areas of the company," said Mr.

Alkermes plc announced today that its corporate presentation will be webcast live at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 2:30 p.m. EST from the Waldorf=Astoria Hotel in New York City.

Novo Nordisk reported earnings of $1.51 per American Depository Receipt , in the fourth quarter 2011, much above the Zacks Consensus Estimate of $1.24. Earnings were also ahead of the prior-year earnings of $1.35 per ADR.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia DUBLIN-- --Alkermes plc today reported financial results for its third quarter of fiscal 2012, which ended on Dec.

Last Friday, the Food and Drug Administration finally approved Bydureon, a once-weekly diabetes shot developed by Amylin Pharmaceuticals and Alkermes PLC .

Richard Pops, Chairman and CEO of Alkermes plc, testified today on behalf of the Biotechnology Industry Organization before the House Energy and Commerce Subcommittee on Health during a hearing entitled, "Reauthorization of PDUFA: What It Means for Jobs, Innovation and Patients." In his testimony, Pops stressed the need for a quick reauthorization ... (more)

Alkermes plc recently announced the commencement of an open-label pilot study of Vivitrol in adult prisoners who have a history of pre-incarceration of opioid dependence, a chronic brain disorder.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Alkermes plc Initiates Open-Label Pilot Study of VIVITROLA to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence DUBLIN-- ... (more)

By Brett Chase Shares of Amylin Pharmaceuticals climbed Monday after the biotech company ALKS ), didn't fare as well, ending the day slightly down.

Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 10:50 a.m. in New York.

Alkermes 's stock had its "buy" rating reiterated by analysts at Jefferies Group in a research report issued to clients and investors on Monday.

The top after-market NASDAQ gainers Friday were: Amylin Pharmaceuticals, Alkermes, Momenta Pharmaceuticals, First Solar, Firsthand Technology Value Fund and Brooks Automation.

Amylin Pharmaceuticals Inc. and Alkermes Inc. : The drugmakers succeeded in their third attempt to gain U.S. clearance for Bydureon, a once-weekly version of Amylin's diabetes shot.

By clicking the "Like" button you will receive a daily update on ALKS . MarketWatch will post an end-of-day news and price summary to your Facebook news feed.

Alkermes Inc. and its California partner Amylin Pharmaceuticals Inc. have finally won approval from the FDA for the diabetes drug Bydureon after years of attempts.

Alkermes plc will host a conference call at 8:30 a.m. EST on Thursday, Feb. 2, 2012, to discuss the company's financial results for the third quarter of fiscal 2012.